Tsakiris D A, Marbet G A
Gerinnungs- und Fibrinolyselaboratorium, Universitätskliniken, Kantonsspital, Basel.
Ther Umsch. 1992 Dec;49(12):833-6.
Treatment of venous thromboembolism aims at the reduction of mortality of massive pulmonary embolism, the arrest of further thrombotic processes and at avoiding late post-thrombotic sequelae. Anticoagulation with heparin and oral anticoagulants remains the treatment of choice. Heparin is administered intravenously or subcutaneously for four to five days. Oral anticoagulation follows thereafter for three to six months or even life-long. Low molecular weight heparin will probably be able to substitute for the unfractionated heparin in the initial treatment phase. Therapeutic fibrinolysis or surgical treatment are considered as alternative treatment modalities. Furthermore, new potent thrombin or platelet inhibitors appear as promising future antithrombotics.
静脉血栓栓塞症的治疗旨在降低大面积肺栓塞的死亡率，阻止进一步的血栓形成过程，并避免血栓形成后的晚期后遗症。使用肝素和口服抗凝剂进行抗凝治疗仍然是首选治疗方法。肝素通过静脉或皮下给药四至五天。此后进行三至六个月甚至终身的口服抗凝治疗。低分子量肝素可能能够在初始治疗阶段替代普通肝素。治疗性纤维蛋白溶解或手术治疗被视为替代治疗方式。此外，新型强效凝血酶或血小板抑制剂有望成为未来的抗血栓药物。
